Physician profile
John J Im
NPI 1922298454
$15,815.80
in general payments reported to CMS, 2019-2025
26 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $1,757 · 2021: $3,526 · 2022: $2,705 · 2023: $2,130 · 2024: $2,022 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,895.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,183.99 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,739.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $1,232.50 | 2022-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $1,200.55 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $1,182.94 | 2020-2021 | |
| Sk Life Science, INC. | $799.97 | 2020-2025 | Xcopri |
| Lundbeck LLC | $771.36 | 2021-2025 | Vyepti |
| Amgen INC. | $668.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $592.99 | 2019-2020 | |
| Abbvie INC. | $528.55 | 2021-2025 | |
| Harmony Biosciences LLC | $433.43 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $338.88 | 2022 | |
| Impel Pharmaceuticals INC. | $334.50 | 2022 | |
| Acadia Pharmaceuticals INC | $285.21 | 2024-2025 | Nuplazid |
| Avadel Cns Pharmaceuticals, LLC | $220.40 | 2023-2025 | Lumryz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.80 | 2019 | |
| Celgene Corporation | $156.72 | 2020-2021 | |
| Tg Therapeutics, INC. | $131.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $113.45 | 2021 | |
| Mdd US Operations, LLC | $112.37 | 2019 | |
| C2n Diagnostics, LLC | $107.36 | 2025 | Precivityad2 |
| Boston Scientific Corporation | $105.69 | 2020 | |
| Bioventus LLC | $100.84 | 2021 | |
| Biogen, INC. | $99.75 | 2021 | |
| Eisai INC. | $97.69 | 2022 | |
| Corium, LLC | $90.92 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.